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Background: Guidance in the United States and United
Kingdom has included cognitive behavior therapy for psy-
chosis (CBTp) as a preferred therapy. But recent advances
have widened the CBTp targets to other symptoms and
have different methods of provision, eg, in groups. Aim:
To explore the effect sizes of current CBTp trials including
targeted and nontargeted symptoms, modes of action,
and effect of methodological rigor. Method: Thirty-four
CBTp trials with data in the public domain were used as
source data for a meta-analysis and investigation of the
effects of trial methodology using theClinical Trial Assess-
ment Measure (CTAM). Results: There were overall ben-
eficial effects for the target symptom (33 studies; effect
size 5 0.400 [95% confidence interval {CI} 5 0.252,
0.548]) as well as significant effects for positive symptoms
(32 studies), negative symptoms (23 studies), functioning
(15 studies), mood (13 studies), and social anxiety (2 stud-
ies) with effects ranging from 0.35 to 0.44. However, there
was no effect on hopelessness. Improvements in one domain
were correlated with improvements in others. Trials in
which raters were aware of group allocation had an inflated
effect size of approximately 50%–100%. But rigorous
CBTp studies showed benefit (estimated effect size 5
0.223; 95% CI 5 0.017, 0.428) although the lower end
of the CI should be noted. Secondary outcomes (eg, nega-
tive symptoms) were also affected such that in the group of
methodologically adequate studies the effect sizes were not
significant. Conclusions: As in other meta-analyses, CBTp
had beneficial effect on positive symptoms. However, psy-
chological treatment trials that make no attempt to mask
the group allocation are likely to have inflated effect sizes.
Evidence considered for psychological treatment guidance
should take into account specific methodological detail.
Key words: CBTp/schizophrenia/meta-analysis/trials/
symptoms/functioning
Introduction
Cognitive behavior therapy (CBT) has been accepted as
a treatment for affective disorders for a number of years
and has been fully integrated into services since the 1980s.
However, despite the case studies by Beck
1 and Shapiro
and Ravenette
2 in the 1950s,’ specific symptom interven-
tionsforschizophreniadidnotappearuntilmuchlater.Psy-
chotherapyforschizophreniaintheformofpsychodynamic
therapies had been discredited and during the period of
deinstitutionalization symptoms were treated merely as
behaviors to be extinguished (eg, Liberman et al
3 and
Meichenbaum and Cameron
4). However, despite earlier
optimism neither medication nor behavioral treatments
successfullyextinguishedsymptomswhichwereeitherpres-
entsporadicallyorremainedcontinuouslydespiteadequate
treatment. Theoretical underpinnings such as the stress-
vulnerability models were developed to understand not
only the development of the disorder but also its mainte-
nance. These also began to be informed by research on
expressed emotion (eg, Brown et al
5 and Butzlaff and
Hooley
6) and so began to include social and psychological
markers as well as biological ones. The difficulty in identi-
fyingrigorousandunambiguouspsychosocialmarkersmay
have hampered further development of this area.
CBT for affective disorders became accepted in the
health services through government guidelines (eg, UK
National Institute for Health and Clinical Excellence),
but it also increased its theoretical research base. It
was inevitable that eventually some of the developed
techniques would be used for people with a diagnoses
ofschizophrenia.Thefirst controlled studieson cognitive
behavior therapy for psychosis (CBTp) emerged in the
early 1990s in the United Kingdom, and this treatment
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523has developed and included some of the theoretical
underpinnings of CBT for other disorders. However,
unlike CBT for other disorders, which have its roots in
Beck Philadelphia Institute, CBTp developed indepen-
dently perhaps because the main research bases for the
2 types of CBT were separated by the Atlantic Ocean.
There is much speculation and argument about why
CBTp emerged first in the United Kingdom, but it
may be that the different service structures in the United
Kingdom within which clinical psychologists worked
were more encouraging for nonmedical approaches to
drug-resistant psychotic symptoms. The implementation
of CBTp was against a tide of skepticism about the de-
velopment of psychotherapy for people with psychosis in
both countries and specific evidence of poor outcomes.
7
There was also optimism about the likelihood of im-
proved medication now somewhat tempered by the Clin-
ical Antipsychotic Trials in Intervension Effectiveness
8
and Cost Utility in the Latest Antipsychotic Drugs in
Schizophrenia Study trials
9 and the positive evidence
on behavioral approaches to psychosocial rehabilitation
which may have contributed to resistance about the de-
velopment of this form of treatment. However, although
the practice of CBTp was enthusiastically grasped by
UK clinical psychologists, it has now also developed
in the United States with studies approaching the provi-
sion of CBTp differently, eg, by more group-based
approaches. Again, service structures and the availability
of skilled clinical psychology staff probably contribute to
thesevariations.WithintheUnitedKingdom,psycholog-
ical treatments are typically individualized and based
upon an idiosyncratic case formulation (see Tarrier
and Calam
10 and Tarrier
11). In the United States, the
recent move to more evidence-based practice has been
to counter the past standard practice of providing psy-
chological treatment from a nonsystematic, nonmanual-
ized perspective. Thus, even if the actual intervention
techniques used were similar in the United States and
the United Kingdom, their strategic application could
differ.
Reviews of studies of CBTp have suggested that they
are useful for the treatment of schizophrenia.
12–23 The
next step is therefore the incorporation of these treat-
mentsintoservices. IntheUnitedKingdom,the National
Institute for Clinical Excellence included cognitive be-
havior therapy (CBTp) in its preferred list of treatments
for schizophrenia.
24 UK National Health Services are
now implementing this guidance because patients in
UK services have the right to expect that this treatment
will beavailable.Thistherapyhasalso beenconsideredin
the Schizophrenia Patient Outcome Report Team guid-
ance in the United States and has been recommended.
25
There are now more published studies available, and
therehasbeenanexpansionofthelikelysymptomtargets
for CBTp to include, in addition to positive symptoms,
negative symptoms, depression, and anxiety, and also
some combination therapies to reduce harm for those
who have a dual diagnosis and substance misuse.
26 All
these symptoms have more recently been recognized as
those which hamper recovery and affect quality of life.
Guidance decisions are mainly based on evidence from
randomized controlled trials (RCTs), and despite recent
criticisms of their appropriateness in mental health,
27,28
RCTs remain the gold standard by which all treatments
are judged.
29–31 Such trials reflect the scientific method of
demonstrating the value of a new treatment in compar-
ison to an appropriate control group by minimizing all
possible sources of bias which could render unsafe the
conclusion that the new treatment is beneficial.
29 There
are established conventions concerning how clinical trials
should be carried out and analyzed
29,32 and these have
been formalized in the Consolidated Standards for
Reporting of Trials (CONSORT) statement.
33,34
Despite these guidelines, there is still considerable var-
iabilityandroomforimprovementinrigor.Thornleyand
Adams
35reportedthat in 2000(mainlydrug)trials,meth-
odological rigor had not improved to a minimal standard
over a period of 35 years. Such rigor is known to affect
the estimation of treatment effects. For instance, poorer
quality masking of allocation of treatments has been
shown to be associated with up to 40% increased estimate
of benefit in circulatory and digestive diseases, mental
health, obstetrics, and childbirth.
36,37
This raises the question of whether differences in meth-
odologywill also inflatetheeffects ofpsychologicaltreat-
ment trials. Marshall et al
38 report that in 150 nondrug
trials, one-third of the claims that treatment was superior
to control would not have been made if published scales
had been used in the assessment. It is of course possible
that other aspects of the design and method could also
affect the results of psychological treatment trials. But
even though meta-analyses have had a direct effect on
treatment guidance, methodological rigor of individual
trials is hardly referred to,
13,18–23 and the strong claim
has been made that the quality of trials included must
be investigated in order to ensure that meta-analyses pro-
vide valid estimates of the true effects of treatment.
39
Aspects of psychological therapy, in addition to meth-
odology, may also affect the treatment effect, in partic-
ular the content. There have been no investigations of
the different elements of treatment in a direct head-to-
head comparison, but there may be more general influ-
ences that could be investigated in a meta-analysis.
CBTpinschizophreniavariesinitsemphasisoncognitive
and/or behavioral dimensions of therapy and at the
extreme end of the continuum merges with some form
of psychodynamic treatments. Clinical emphasis in any
model is also dependent on the services in which it is pro-
vided and the background professional training of the
therapists which differs from country to country. There
maythereforebe particular differences toexplore in stud-
ies between countries. The superiority of any model has
T. Wykes et al.
524never been investigated, and as we move from efficacy to
effectiveness studies this is an important consideration.
Since the publication of the latest meta-analysis, more
data from newer CBTp trials have become available. The
aim of this article is to look in more detail at this
expanded data set with its extended list of outcomes
and investigate the effects of different methodological
attributes as well as clinical models in the calculation
of benefit. In particular, we will estimate the possible in-
flationofeffectsizeduetolackofmaskingofparticipants
to groups because it has been identified as a potent meth-
odological variable in the inflation of the treatment effect.
Methods
Trial Inclusion
Multiple systematic searches of Embase, Medline, Cur-
rent Contents, Web of Science, PsychInfo, and the
Cochrane Collaborative Register of Trials were per-
formed using the following search terms either as key
terms or as key words:
(SCHIZO* or SCHIZOPHRENIA or SCHIZO-
AFFECTIVE DISORDER) AND (COGNITIVE
THERAPY or COGNITIVE BEHAVIOUR THER-
APY or COGNITIVE BEHAVIOR THERAPY)
AND (RANDOM or RANDOMISED CONTROL
TRIAL or CLINICAL TRIAL).
One hundred forty-one publications were identified
which were hand searched including their reference lists.
In addition, the reference lists from reviews and meta-
analyses
12–23 were hand searched. This produced a total
of 35 articles that were judged potentially eligible for this
review and read independently by 2 of the authors. In
addition, using our own knowledge of work in this
area through conference presentations (2004–2006), the
Beck psychosis networks, and familiarity with appropri-
ate research groups around the globe, one further trial
was addedthathad been submitted.
40 Thisstudyhassub-
sequentlybeen published. The criteria toretain a publica-
tion were
  the studies sample had to contain a majority of people
with a diagnosis of schizophrenia;
  all patients received standard psychiatric care (TAU,
treatment as usual) including appropriate medication;
  in the experimental group, CBT was an adjunct to
TAU;
  there was a control group;
  there was an allocation procedure;
  CBT treatment was targeted at one of the following
(positive or negative symptoms of psychosis, function-
ing, mood, hopelessness/suicidality, or social anxiety).
Trials were excluded if they were uncontrolled, tested
forms of psychotherapy other than CBT, or whose out-
comes did not include symptoms at the end of treatment.
For example, Kemp et al
41 was excluded because its aim
andoutcomeweremedicationcomplianceanditsmethod
was motivational interviewing rather than more con-
ventional CBT. Two studies were excluded because the
authors did not make the data available that was neces-
sary for inclusion in the meta-analysis, leaving a total
sample of 34 studies.
Effect Size Calculation
Effect sizes of the treatment trials were calculated from
the following equation.
19
Effect size=ðMt   McÞ=SDc
where Mt is the mean of the CBTp group at posttreat-
ment, Mc is the mean of the control group at posttreat-
ment,andthisisdividedbytheSDofthecontrolgroupof
participants at posttreatment. Outcome was considered
in relation to positive symptoms, negative symptoms,
functioning, mood, hopelessness, and social anxiety
where such data were available, and the measures chosen
to reflect these outcomes in the calculation of the effect
size was a continuous one. With respect to positive symp-
toms, this was, in most cases, a summary score from a re-
liable measure such as the Positive and Negative
Syndrome Scale (PANSS) or Brief Psychiatric Rating
Scale, but other measures such as Psychotic Symptoms
RatingScaleswere also usedwhen these were unavailable
orwhentheauthorshadpoweredtheirstudyonaspecific
continuous measure. The control group was considered
to be the TAU group or a control adjunct treatment
that had been hypothesized to be inactive for the main
outcome. All effect sizes were recalculated from the study
data except in one case in which the data were insuffi-
ciently reported and so the effect size reported in a previ-
ous meta-analysis was used.
19 The main consideration
was the effect after treatment; so we have not included
any follow-up data.
Measures
FeaturesUsedtoAssessQualityofTrialReports. Alistof
relevant features were extracted from the CONSORT
guidelines
34 that are the current convention for describ-
ing clinical trials in major medical journals, eg, Lancet,
British Medical Journal, Journal of the American Medical
Association, and Archives of General Psychiatry. Expert
opinion from psychologists, psychiatrists, statisticians,
and methodologists was then sought on this checklist.
Theseopinionsprovidedfacevalidity.Individualfeatures
were differentially weighted based on previous data on
methodological characteristics that can influence out-
come (eg, Thornley and Adams
35, Moher et al
36,
Marshall et al
38, Chalmers et al
42, Jadad et al
43, Juni
et al
44, Juni et al
45, Kazdin and Bass
46, and Sterne
et al
47). The resulting list had 15 items grouped into 6
areasof trial design: samplesize and recruitment method,
allocation to treatment, assessment of outcome, control
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Assessing Quality of CBTp Trialsgroups, description of treatments, and analysis (see
below). Items were weighted in score depending on the
importance highlighted by previous methodology articles
and meta-analyses. For example, the total item score for
allocation to treatment group was higher than the section
on descriptions of active treatment.
We did not want to confuse the rating of methodolog-
ical quality with the quality of the report
39,48; so issues
were clarified with the trial researchers, and where neces-
sary data or information were requested that were not
available within the published report. Subsequently, we
made the ratings of methodological quality of each indi-
vidual trial available tothe trial researchers and askedfor
their comments.
Themethodologyareasincludedwithintheratingscale
(Clinical Trial Assessment Measure: CTAM) are de-
scribed below. A more detailed account with specific
scores is given in Tarrier and Wykes.
49
Sample Characteristics
Recruitment via volunteers or referrals of ‘‘suitable’’
patients by clinicians will not produce as representative
a sample as a geographic or epidemiological cohort. In
addition, we have included that sample size should be
based on adequate power calculations.
Allocation to Treatment
The process of random allocation needs to be appro-
priate and clearly described,
50 and the sequence is con-
cealed from the research team because this has been
shown to be associated with larger treatment effects.
51
Assessment of Outcome
Standardized assessment methods should be used
38
and collected independently of treatment by assessors
who were unaware of treatment allocation (normally
called blinded or masked assessment).
Control Groups
A control treatment that includes standard psychiatric
care or TAU is a prerequisite. The use of a control treat-
ment that includes another psychological treatment, such
as supportive counselling or a placebo treatment (eg,
befriending), is desirable to allow the estimation of the
nonspecific effects of treatment to be assessed.
Description of Treatments
Treatments should be described so that they can be in-
dependently replicated; this would be aided by a manual
or protocol. Assessment of adherence to the treatment
protocolor somemethodoftreatmentqualityassessment
should also be carried out. This is an important aspect of
psychologicaltreatmentsthatwillnotbecoveredbymore
generic rating scales of trial quality.
Analysis
The most acceptable methods for statistical analysis
were judged (by an experienced trial statistician) as being
appropriate to the data and the trial design. For instance,
the results should be analyzed on an analyzed-as-
randomized (sometimes referred to as an intention-to-
treat analysis) because it maintains the benefits of
randomization.
32 Some commonly used procedures to
accommodate missing data were not considered to be ap-
propriate, eg, missing value substitution by ‘‘last obser-
vation carried forward’’ because of its underlying
assumptions and likely optimism about the precision
of the extracted effect size.
32
Reliability of CTAM. Independent ratings by 2 of the
authors of an initial 18 studies showed good blind inter-
rater agreement of 0.96. The scale showed adequate in-
ternal consistency (Cronbach a = .697). The total score
and the scores for the 6 domains were used as the out-
come measures. The accuracy of the CTAM scores
was confirmed by the first author of each specific study
in 27 cases. The authors of 6 studies did not comment,
and one was not contactable.
Validity of CTAM. Face validity from experts and the
CONSORT statement have already been described. In
addition, concurrent validity was assessed within an ini-
tial 22 studies by correlation with the scores from 3 other
scales devised to assess methodological rigor.
42,43,52 The
correlations of these scales with the CTAM scores on the
corpus of CBTp data were as follows: CTAM and Jadad,
q = .960, P < .001; CTAM and Chalmers, q = .93,
P < .001; and CTAM and Brown, q = .80, P < .001.
This indicates that CTAM had excellent concurrent val-
idity. Predictive validity will be tested in the relationship
between CTAM scores and effect sizes. It might be
expected that less rigorous studies (ie, more potential
for bias) will produce larger effect sizes.
Rating of the Emphasis of the Clinical
Model. Descriptions of the clinical characteristics of
the underlying model and clinical techniques included
in each study were extracted from the written reports,
and all identifiers were removed so that the rater could
remain masked to the identity of the study. An indepen-
dent qualified CBTp psychologist ranked the studies on
the basis of least to most behavioral. This was defined on
the basis of whether there was more emphasis on issues
in the past, eg, historical variables, which might have an
impact on the future (least behavioral), or whether there
was a focus on the here and now and the interpretation of
current events (more behavioral).
Results
The Trials
Thirty-fourstudiesofCBTpwereidentifiedthroughpub-
lished records, conference presentations, and networks of
CBTp specialists throughout the world. Data were avail-
able either in their published form or, where necessary,
were made available to the authors.
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patients in the community, 7 studies of acutely ill
patients, 1 of chronic inpatients, and 1 contained a mixed
population. Twenty studies were from the United
Kingdom; 5 from the United States; 2 each from
Germany, Australia, and the Netherlands; and 1 each
from Canada, Italy, and Israel. The average number of
participants in each trial was 58.2 (range 11–353), and
the median proportion of those lost to follow-up assess-
ment was 14.5% (range 0%–45%). Seven studies (21%)
had a dropout rate higher than 25%, which is the level
above which many statisticians would question the valid-
ity of the study findings.
The studies had varied targets of intervention. Most
focused on positive symptoms (one study concentrated
on reducing the powerfulness of the voice
53), although
2 targeted negative symptoms, 2 targeted functioning,
and 2 targeted social anxiety. Twenty-seven studies
were individual CBTp, while 7 studies were group
CBTp. All studies have continuous measures of outcome
for the target symptom.
Table 1 shows the total number of studies reporting an
outcome with the number of studies whose intervention
was targeted at a specific symptom shown in parenthesis.
Table2showsasummaryofthe34studiesincludedinthe
analyses including the methodological quality ratings.
Trial Quality
The maximum score for the CTAM is 100, and in this
sample of trials, the mean score was 61.2 (SD 18.1) with
a median of 56 and a range of 27–100 (see table 2). There
wassomevariabilityinmethodology.All,except4studies,
had random allocation, and 5 studies did not have inde-
pendent assessments of outcome measures (but they
were different studies). However, few reports adequately
describedtheprocessofassessorblindingorverifiedblind-
ingattheendofthestudy.Morethanhalfofthestudiesdid
not use a statistical method that was judged to take satis-
factory account of dropouts from assessment. Methodo-
logical criteria have evolved over time with later trials
showing higher CTAM scores (Spearman correlation =
.393,P = .02)andanincreasedqualityinallocationpolicy
(ie,independencefromtheresearchteamandtruerandom
allocation) (Spearman correlation = 0.463, P = .006).
Trials with larger sample sizes have better CTAM scores
which probably reflects the likelihood of larger invest-
mentsbyfundingorganizationstobeinhigherqualitytri-
als (Spearman q = .596, P < .001).
Clinical Emphasis
The 34 trials differed in their clinical emphasis with some
representing schema-dependent therapy and one even
reporting an emphasis on the ‘‘links between current
symptoms and earlier real life events.’’ At the other
end of the scale studies reported an emphasis on be-
havioral homework, relaxation, and the development
ofbehavioral coping strategies. There was, however, con-
siderableoverlap.Behavioralrehearsal,eg,and therever-
sal of avoidance (or safety behaviors) were common to
many of the approaches irrespective of their stated em-
phasis. The clinical emphasis as ranked by an indepen-
dent CBTp specialist is given in table 2. Although not
significant, group studies were more likely to have
a more behavioral emphasis than individual studies
(t = 1.6, df = 32, 95% CI =  14.8 to 1.9).
Clinical Model and Trial Quality
There was no significant association between the empha-
sis of the clinical model and methodological rigor of the
trials as measured by the CTAM total score (q =  .19,
P = .28). Neither the total score nor the domain scores
for CTAM were associated with clinical emphasis.
Study Origin and Trial Quality
Those studies originating outside the United Kingdom
had smaller sample sizes. In fact, only 2 non-UK studies
had a sample size that was above 27 participants per
group, which is the smallest sample size likely to identify
a modest clinically significant effect.
46 Overall trial qual-
ity was significantly higher in UK trials (mean CTAM
score: UK 67.6, non-UK 52.1; t =  2.69, 95% CI =
 27.4 to  3.8). The differences in method, apart from
sample size, were (1) in the way the sample was drawn—
non-UK sites mainly relying on convenience samples, (2)
the quality of random allocation, and (3) the quality of
control group. There were no differences in the target
symptomeffectsizes orthe clinical emphasisofthe model
Table 1. Number of Studies Providing Specific Outcomes (Numbers in Parenthesis are Those Studies That Specifically Targeted that
Outcome)
Positive
Symptom
Negative
Symptom Functioning Mood Hopelessness Social Anxiety Total
Individual CBTp 27 (24) 19 (1) 12 (2) 12 (0) 3 (0) 0 (0) 27
Group CBTp 5 (4) 4 (1) 3 (0) 3 (0) 1 (0) 2 (2) 7
Total 32 (28) 23 (2) 15 (2) 15 (0) 4 (0) 2 (2) 34
Note: CBTp, cognitive behavior therapy for psychosis.
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Trial Year
United
Kingdom
Individual/
Group
Primary
Aim
Positive
Symptom
Effect Size
Total CTAM
(Max 100)
Sample
(Max 10)
Allocation
(Max 16)
Assessment
(Max 32)
Control
(Max 16)
Analysis
(Max 15)
Treatment
Description
(Max 11)
Clinical
Model
Milton et al
54 1978 Y I P 0.78 52 0 13 26 10 0 3 25
Tarrier et al
55 1993 Y I P 0.35 49 2 10 16 16 5 0 32
Garety et al
56 1994 Y I P 0.55 39 2 0 16 6 9 6 14.5
Bentall et al
57 1994 Y I P 0.29 53 2 10 23 10 5 3 11
Drury et al
58 1996 Y I P 0.93 53 2 13 16 10 9 3 23
Kuipers et al
59 1997 Y I P 0.37 63 7 16 13 6 15 6 4.5
Tarrier et al
60 1998 Y I P 0.73 96 10 16 32 16 11 11 32
Daniels
61 1998 N G N 0.64 42 2 0 26 6 0 8 34
Levine et al
62 1998 N G P 2.36 56 0 10 26 6 11 3 32
Pinto et al
63 1999 N I P 0.99 44 2 10 16 10 0 6 28
Haddock et al
64 1999 Y I P  0.49 56 2 10 26 10 5 3 24
Halperin et al
65 2000 N G SA n/a 27 2 10 6 6 0 3 8.5
Sensky et al
66 2001 Y I P 0.14 81 7 16 26 10 11 11 2.5
Bailer et al
67 2001 N I N 0.34 38 2 0 16 6 11 3 20
Barrowclough et al
26 2001 Y I P 0.26 80 10 16 29 6 11 8 14.5
Lewis et al
68 2002 Y I P 0.12 100 10 16 32 16 15 11 20
Turkington et al
69 2002 Y I P 0.23 77 10 16 26 6 11 8 14.5
Durham et al
70 2002 Y I P  0.32 84 7 16 29 16 5 11 20
Hall and Tarrier
71 2002 Y I P 0.88 41 2 16 6 6 5 6 29.5
Valmaggia et al
72 2002 N I P 0.32 62 2 13 26 10 11 0 8.5
Granholm et al
73 2002 N I F 0.62 40 2 10 16 6 0 6 14.5
Gumley et al
74 2003 Y I P 0.19 53 10 10 16 6 5 6 6
Rector et al
75 2003 N I P 0.28 55 2 13 26 6 5 3 7
Jolley et al
76 2003 Y I P  0.10 75 5 16 26 6 11 11 2.5
Kingsep et al
77 2003 N G SA n/a 56 2 0 26 6 11 11 29.5
Trower et al
53 2004 Y I CH 1.75 71 7 16 26 6 5 6 1
Wiersma et al
78 2004 N I P 0.65 54 7 16 16 6 6 3 26
Bechdolf et al
79 2004 N G P 0.02 67 7 16 26 10 5 3 20
Startup et al
80 2005 Y I P 0.44 64 10 16 16 6 5 11 45
Cather et al
81 2005 N I P 0.04 56 2 16 26 6 0 11 27
Granholm et al
82 2005 N I F  0.07 87 10 13 32 6 15 11 14.5
Wykes et al
83 2005 Y G P 0.02 79 10 16 26 6 15 6 20
Gaudiano and
Herbert
84
2006 N I P 0.47 45 2 14 3 6 15 6 10
Barrowclough et al
40 2006 Y G P 0.04 87 10 16 29 6 15 11 14.5
Note: CTAM, Clinical Trial Assessment Measure; primary aim: P, positive; N, negative; SA, social anxiety; CH, command hallucinations; F, functioning; n/a, not applicable;
y, yes; N, no.
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.between studies originating inside and outside the United
Kingdom although it was clear that the UK studies
spanned the whole continuum of emphasis whereas
non-UK sites tended to have a more behavioral
emphasis.
Several meta-analyses were conducted on this corpus
of data in relation to the various outcomes as well as
the targeted outcomes. The outcome under investigation
foreachmeta-analysiswas thetotal symptomscoreonan
appropriate scale, eg, PANSS positive symptom score,
PANSS negative symptom score, Global Assessment of
Functioning for functioning, Calgary Depression Scale
for depression, Brief Social Phobia Scale for social anx-
iety, and Beck Hopeless Scale for hopelessness/suicidality
(see Method for decisions on choice of outcomes).
Meta-analyses of All CBTp Trials in Relation to Various
Symptom and Functioning Outcomes
Six separate meta-analyses were carried out on the data
using a random-effects model (see Everitt and Pickles
32
and Fleiss
85) which was applied to the effect sizes
obtainedfromtheCBTptrialswhichreportedthevarious
outcomes
  target symptoms (as specified by the research team in
their publication),
  positive symptoms,
  negative symptoms,
  functioning,
  mood,
  hopelessness.
Heterogeneity of effect sizes was assumed (and later
confirmed for many analyses, see table 3); so a random-
effects (RE) model rather than a fixed-effects model was
adopted
32,85 (see table 3). Even in the few instances where
the test for homogeneity of effect sizes was not signifi-
cant, the RE model was still used because of concerns
about the test’s lack of power. The results of the individ-
ual meta-analyses are given in table 3. The table also pro-
vides the estimated overall effect size, the 95% confidence
intervals (CIs), and the usual chi-square test of the homo-
geneity of the effects. A significant chi-square value indi-
cates heterogeneity in the effect sizes. Not all trials
reported all outcomes, and not all trials targeted partic-
ular outcomes; so the initial analysis reports the results of
a meta-analysis of the indicated target for the study. In
the 34 trials, only 33 CBTp trials reported this outcome
for the symptom that the trial was targeting. Because
there were only 2 studies for the assessment of social anx-
iety, neither heterogeneity nor CIs are provided.
In terms of the relationships between different out-
comes, there are significant correlations between
improvements in positive symptoms and a worsening
in hopelessness (R =  0.978, P = .022, N = 4), improve-
ments in negative symptoms (R = 0.830, P < .001,
N = 23), and some evidence of improved functioning,
but this did not quite reach significance (R = 0.510,
P = .052, 2 tailed, N = 15). Improvements in negative
symptoms were related to improvements in functioning
(R = 0.656, P = .021, N = 12). There is also a positive re-
lationship between improvements in functioning and
improvements in mood (R = 0.954, P = .003, N = 6).
Theseresultssuggestthatthereisarelationshipbetweendif-
ferent outcomes in that targeting one outcome may have
positive (and sometimes detrimental) effects on others.
Individual and Group CBTp: Comparison of Outcome in
Relation to the Target Symptom
To address this question, a random-effects model was ap-
plied separately to the individual CBTp studies (number
of studies = 26, total number of participants = 1565) and
to the group CBTp studies (number of studies = 7, total
number of participants = 399) in relation to the outcome
for the target symptom. For the individual CBTp studies,
the estimated effect size was 0.415 (SE = 0.08); the corre-
sponding figure for the group CBTp studies was 0.386
(SE = 0.20). The estimated 95% CI for the difference is
( 0.384, 0.442) suggesting that there is no evidence of any
differenceineffectsizebetweenindividualandgroupCBTp.
Exploration of Heterogeneity of Outcomes Using
Individual CBTp Aimed at Positive Symptoms
There was heterogeneity of effect size noted in the meta-
analyses reported above. The purpose of the following
analyses is to investigate this heterogeneity in more detail
withspecific reference toonly those studies that indicated
Table 3. Results of Meta-analyses
Mean Weighted
Effect Size
95% Conﬁdence
Interval
Heterogeneity Test (df),
Significance Level
No. of
Studies
Sample
Size
Target symptom 0.400 0.252, 0.548 74.1 (32), signiﬁcant at the 5% level 33 1964
Positive symptoms 0.372 0.228, 0.516 61.7 (31), signiﬁcant at the 5% level 32 1918
Negative symptoms 0.437 0.171, 0.704 118.1 (22), signiﬁcant at the 5% level 23 1268
Functioning 0.378 0.154, 0.602 36.7 (14), signiﬁcant at the 5% level 15 867
Mood 0.363 0.079, 0.647 52.7 (12) signiﬁcant at the 5% level 15 953
Hopelessness  0.190  0.547, 0.166 10.0 (3), not signiﬁcant 4 431
Social anxiety 0.353 n/a n/a 2 61
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chose those that provided CBTpin a more traditional ap-
proach by an individual therapist. This has 2 bene-
fits—the studies are homogenous in terms of their
mode of treatment provision and treatment target but
also report on CBT because it was originally developed
asatherapyaimedatresidualsymptoms.Thisgavealarge
sample because the majority of studies were individual
CBTp aimed at reducing positive symptoms (number of
studies = 24, total number of participants = 1450). These
studies were therefore investigated in more detail to un-
derstand whether methodological rigor (or lack of it) and
clinical emphasis affected the estimate of effectiveness.
Meta-analysisofIndividualCBTpTrialsAimedatPositive
Symptoms. A random-effects model was applied to the
effect sizes obtained from the 24 individual CBTp trials
aimed at positive symptoms, leading to an estimated
overall effect size of 0.399 with a 95% CI of 0.243,
0.556. The usual chi-square test of the homogeneity of
the trials took the value 40.0 with 23 df, which is signif-
icant at the5% level. There is evidenceofheterogeneityof
effect size in the 24 studies. A forest plot (see Everitt
86)o f
the effect sizes and associated95% CIs orderedbyCTAM
score is shown in figure 1.
Relationship Between Methodological Quality, Clinical
Emphasis, and Effect Size. To investigate the various
relationships, a weighted analysis is necessary because
the estimated effect sizes clearly have different precisions
and any unweighted analysis ignores this feature of the
data. The weight applied to a study was the reciprocal
of the sum of the estimated between study variance
and the estimated variance of the effect size for the study
(see Everitt
86). The former is found from the random-
effects model used in the meta-analysis (see above),
and the latter is approximated by the sum of the sample
sizes for the experimental and control groups divided by
the product of these sample sizes (see Fleiss
85). Because
theTroweretal
53trialhadadistinctfocusofintervention
(command hallucinations), the results of some analyses
wererepeatedtochecktheeffectsofthisstudyontheout-
come of the analysis.
Relationship of CTAM and Effect size. The simple cor-
relation was significant whether or not Trower et al
53
study was excluded (Spearman q =  .485, P < .02).
However, in a weighted effect size analysis including
the Trower et al
53 study, the estimated regression coeffi-
cient of effect size on CTAM (found from a weighted
regression—see above) was  .0056 with 95% CI
Fig. 1. Forest Plot of the Effect Sizes for the Trials Shown in Table 2.
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86) of effect
size against CTAM in which the radii of the circles
represent the SE of the effect size of a study is shown
in figure 2. The tendency is, as expected, for smaller
CTAM scores to be associated with larger effect sizes,
but the relationship is weak suggesting that other factors
not included in the CTAM scale also affect the trial
results.
Relationship Between Domains of CTAM and Effect
Size. The estimated regression coefficients for the var-
ious domains of CTAM and effect size and their esti-
mated CIs are given in table 4. In these analyses, none
of the regression coefficients are significant. However,
when the Trower et al
53 study was excluded, the relation-
ship of the assessment domain and effect size became sig-
nificant (the estimated regression coefficient was  .017
(95% CI =  0.032,  0.002). All but one domain is in
the expected direction of higher effect sizes with poorer
methodology within a particular domain.
Masked and Unmasked Assessment. One of the main
questions of interest in this study was whether masking
of the assessor to the treatment group allocation can
lead to different effect sizes because this has been shown
for a number of medication studies. There is also some
indication of a relationship because the assessment do-
main includes group masking which was found in the
results above. To address the specific question of mask-
ing, a random-effects model was applied separately to the
14 masked studies and to the 10 unmasked studies. For
the masked studies, the estimated effect size was 0.307
(95% CI = 0.087, 0.527); the corresponding figure for
the unmasked studies was 0.492 (95% CI = 0.312,
0.672). There is a tendency for the unmasked studies
to be overoptimistic about the effects of CBTp, with
effect sizes of 50%–100% higher than those found in
masked studies. Even more telling perhaps is the
lower end of the 95% CI (0.087, 0.527) for the masked
studies.
Relationship Between Clinical Emphasis and Effect
Size. The analyses were carried out excluding the
Trower et al
53 study because the clinical emphasis in
this study of so different. The estimated regression
coefficient of .014 (0.0004, 0.028) was significant and
suggeststhatmorebehavioraltreatmentsproducegreater
effect sizes.
Publication Bias. Possible publication bias was investi-
gated by a funnel plot (effect size against precision) (see
figure 3). The absence of studies in the left-hand corner
of this plot is usually taken as an indication of possible
publication bias. The current plot does not appear to
indicate any evidence of a worrying publication bias
and so suggests that the estimated effect size found
from the random-effects model applied to the 24 studies
is realistic.
Fig. 2. A Bubbleplot of Effect Size Against Clinical Trial
AssessmentMeasure(CTAM)Score(RadiioftheCirclesRepresent
the SE of the Effect Size).
Table 4. Relationship Between Methodological Rigor and Effect
Size
Domain
Regression
Coefﬁcient
95% Conﬁdence
Interval
Sample  .018 ( 0.065, 0.039)
Allocate .002 ( 0.058, 0.062)
Assess  .014 ( 0.035, 0.007)
Control  .013 ( 0.056, 0.030)
Analysis  .020 ( 0.057, 0.017)
Treat  .002 ( 0.049, 0.045)
Fig. 3. Funnel Plot.
531
Assessing Quality of CBTp TrialsRelationship Between Methodological Quality and Effect
Size in Each of the Outcome Domains
Because there was some relationship between methodo-
logical quality and effect size, the outcomes shown in ta-
ble 3 were investigated in terms of the relationship
betweenstudieswherethemethodologybycurrentstand-
ards might be considered adequate. Because there was no
specific domain that was poor in all the studies, a cutoff
score for the CTAM total of 65 was taken to indicate ad-
equate methodology. This produced 12 studies with ad-
equate methodology and 22 with poorer methodology.
The results of the meta-analyses in each of these groups
are shown in table 5. For each symptom area, the effect
size is larger for the low CTAM studies. This difference is
significant for the target symptom and for assessments of
mood, and the CIs for the difference is highly skewed for
all the other measures. The CIs for the weighted effect
sizes in higher CTAM scoring studies are also not signif-
icant for negative symptoms, functioning, and mood.
However, even when the more stringent criterion is
used to define the groups, there are still modest effect
sizes for positive symptoms and the targeted symptom.
Discussion
What Variability Is There Between Studies?
This is the largest review of CBTp trials containing 20
more trials than the most comprehensive meta-analysis
21
and 475 more participants. The field has certainly now
matured so that there are now nearly 6 times as many
patients as in the first reported meta-analysis.
19 The av-
erage number of participants in each trial is relatively
small (average 66), but this is the same as for drug trials
in schizophrenia over the past 35 years.
35
The measure of trial quality, CTAM, detected method-
ological variability even in studies that had already
passed some methodological inclusion criteria. In fact,
in other assessments of quality, these studies would prob-
ably have been considered ‘‘good research evidence.’’
25
The methodology scores were not bimodal, and there
was also variability in items scoring highly among the tri-
als.Althoughtherewasvariability,thereissomeevidence
that trials improved their quality and their size over time
with larger more rigorously controlled trials appearing
more recently. Similar variation has been noted in
CBT and suicidal behavior and therapies involving vir-
tual reality although the trials investigated here were
of higher quality and were more likely to be large enough
to identify clinically significant effects.
87,88
As well as variability in the methodologies adopted
there is also variability in the types of therapy offered un-
der the single umbrella of CBTp. We tried to capture this
in our ranking of emphasis, but even if the emphasis was
similar, the ingredients used both within a particular
study and certainly within a particular participant are
likely to be variable (see Tarrier and Wykes for a more
detailed discussion
49). Our independent rating of clinical
emphasis was not linked to methodological rigor. As
expected, studies from the United Kingdom had higher
methodology scores because this site had developed
the CBTp study models which then led to the larger
and more rigorous studies. Other sites are now building
from initial pilot and feasibility studies to more signifi-
cant RCTs.
Is CBTp Effective?
The obvious further question is, for what outcome? Be-
cause CBTp was designed to specifically target positive
symptoms, we have used this data set to provide the
Table 5. Effect Sizes by Methodological Quality
Mean Weighted
Effect Size
95% Conﬁdence
Interval
Heterogeneity Test (df),
Significance Level
No. of
Studies
Sample
Size
95% Conﬁdence
Interval of Difference
Target symptom
High CTAM 0.223 0.017, 0.428 27.73 (11), signiﬁcant at the 5% level 12 1124 0.038, 0.584
Low CTAM 0.534 0.343, 0.725 35.35 (20), signiﬁcant at the 5% level 21 840
Positive symptom
High CTAM 0.222 0.016, 0.427 27.83 (11), signiﬁcant at the 5% level 12 1124  0.002, 0.532
Low CTAM 0.487 0.311, 0.664 27.35 (19), not signiﬁcant 20 794
Negative symptom
High CTAM 0.206  0.104, 0.516 28.33 (8), signiﬁcant at the 5% level 9 631  0.100, 0.908
Low CTAM 0.610 0.200, 1.020 83.33 (13), signiﬁcant at the 5% level 14 637
Functioning
High CTAM 0.147  0.172, 0.466 8.49 (4), not signiﬁcant 5 347  0.058, 0.782
Low CTAM 0.509 0.221, 0.797 23.04 (9), signiﬁcant at the 5% level 10 520
Mood
High CTAM 0.084  0.154, 0.322 9.21 (5), not signiﬁcant 6 685 0.048, 1.144
Low CTAM 0.680 0.174, 1.186 32.96 (8), signiﬁcant at the 5% level 9 268
Note: CTAM, Clinical Trial Assessment Measure.
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is yes it has modest effects. This is the conclusion of other
meta-analyses in this area.
12–16,18–23 The current meta-
analysis was methodologically rigorous, for instance,
we carried out assessments based on weighted effect sizes
that earlier meta-analyses failed to do (eg, Rector and
Beck
18 and Gould et al
19), included all eligible trials
thatothersfailedtodo(eg,Pillinget al
13),andconsidered
methodological variability that others failed to do (eg,
Pfammatter et al
20). Although the overall effect size on
positive symptoms was lower than assessed by others
(eg, Rector and Beck
18 and Gould et al
19), it was in
line with recent evaluations using a smaller data set
but similar rigorous methods
21 (effect size = 0.35, no
studies = 15). Even when a stringent methodological cri-
terion is adopted a modest significant positive effect size
remains.
But perhaps more interesting is that this meta-analysis
shows that CBTp may have an effect on other outcomes
even if these were not the specific targets of the therapy.
The effects for all outcomes were modest, and with the
exception of hopelessness (4 studies) the effects were
significant overall although these results are more spec-
ulative because they seem to be affected by the method-
ological rigor of the study. However, for hopelessness,
not only did this outcome showed homogeneity of effect
size but also 3 out of the 4 studies showed negative ef-
fects suggesting that current CBTp approaches are not
beneficial for this particular outcome and may even be
detrimental.
There are also relationships between outcomes such
that some outcome improvements seem to be correlated
suggesting that irrespective of the actual target, CBTp
has wider beneficial impacts. The mode of transmission
of these benefits and the timing of such overlapping ben-
efits is not clear and would require further prospective
investigation using individual level data.
The mode of provision of CBTp also seems to have lit-
tle effect with group studies showing the same modest
effects. This may make them more cost-effective for par-
ticular outcomes and is a mode of presentation that is
more highly developed in the United States. However,
there are fewer studies testing group therapy and further
work in this area is merited to investigate how much
improvementisnecessaryandtoreducetheheterogeneity
of the effect sizes. Work by both Wykes et al
83 and
Barrowclough et al
40 on the clustering of effects within
groups provides an analytic strategy for identifying fac-
tors that predict good outcomes and therefore the likeli-
hood of increased efficacy of group treatment.
Can We Account for Heterogeneity in Effect Size?
We had thought that by choosing a more homogenous
sample of studies, ie, those that provided CBTp individ-
ually and which specifically targeted positive symptoms,
we would reduce the heterogeneity in the effect sizes, but
again although the effects were modest (0.399) there was
still significant heterogeneity.
In our subsample, the trials with poorer methodology,
as measured by CTAM, tended to have larger effect sizes,
although the relationship is relatively weak. Only about
60% of meta-analyses carry out quality assessments of
methodologyandevenfewer(50%)actuallylinkthesetri-
alqualityassessmentstotheinterpretationofthefindings
in meta-analyses
89 or specifically to psychological treat-
ment studies. The measure we derived for the quality as-
sessment is reliable and has evidence of both internal and
external validity, and although there may be further
developments it is clear that the CTAM list provides
a start for improving the methodological rigor specifi-
cally of psychological treatment trials.
Some assessments of trial quality have been found se-
riously to affect the assessment of treatment effectiveness
in other areas of treatment.
90 However, in our assess-
ments, no specific domain dominated. This may be be-
cause of the heterogeneity of the trial methodologies
themselves
91suggestingthat somestudiesareparticularly
adept at one aspect of methodological rigor and not
others. This is hopeful because it suggests that with
enough effort all aspects could be improved and high lev-
els of methodological rigor would be possible. Method-
ological quality also affected the effect sizes for the other
outcomes investigated making most not significant. So
potential methodological quality variation can (and
did) lead to bias and reduction in precision of the esti-
mates of the therapy’s effectiveness.
90–92 These results
are no different to those that have been found for
drug and other medical treatment, and the results
reported here are salutary for all psychiatric studies.
The most influential individual methodological vari-
able was masked assessment, which is known to be dif-
ficult to carry out in psychological treatment trials.
When masked assessment was attempted (we do not
know how successful this was), then there was nearly
a 60% reduction in the effect size. This compares with
the 34% inflation of effect size reported in other studies.
39
In order to ensure true randomization, the random allo-
cation sequence should be irreversibly administered and
should be concealed to the individuals in charge of
enrolment. Knowledge of possible upcoming allocation
may permit selective allocation of patients through
some form of manipulation. This might result in those
more amenable or more likely to benefit from the treat-
ment being allocated differentially between groups. The
effects on subsequent measures are also essential to
consider. It is obvious that assessors may well be biased
in their assessment, particularly their expectation of pos-
itive changes if they know the group allocation. This is
a problem not only in the assessment of psychological
treatments but in many other fields. In a recent assess-
ment based in Denmark, the majority of the trials
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whether they used data in the trial protocol or the trial
publication.
93
Other meta-analyses have suggested that CBTp for
positivesymptomsis moreeffectiveforacutepopulations
compared with chronic ones, but these conclusions may
also be tempered by overall trial quality. For instance, in
the studies identified by Zimmerman et al,
21 the acute
studies had only 1 in 3 with adequate methodology (as
defined in this article) but for the chronic group 5 out
of 10 had adequate methodology. These methodology
quality differences are likely to have an impact on the ef-
fect size calculations, as was seen in table 5. However,
even with the reduction in effect size, the results of the
meta-analysis on positive symptoms indicates that for
this increased corpus of trials there is a benefit for
CBTp on the positive symptoms of schizophrenia al-
though the lower end of the CI suggests only marginal
benefits. The general results therefore support other
published meta-analyses and systematic reviews that
CBTp should be included in guidance on treatments
for schizophrenia.
There was a trend for clinical models of CBTp that
emphasize more behavioral aspects of treatment to pro-
duce larger effect sizes, and this relationship could not be
accounted for by differences in methodological rigor. So,
studies from all schools of therapy were carried out as
well (or as badly) as each other. Our assessment of the
level of behavioral emphasis was based only on the pub-
lished information on the type of therapy approach. It is
of course quite possible that every client in any study re-
ceived a different amount of the therapy and therefore
a mixture of the behavioral and more cognitive aspects
of the treatment. Assessments of fidelity measure if the
therapy complies with what is expected of CBTp but
rarely do they measure whether all aspects of the therapy
manual were received. If some patients received less of
a ‘‘dose’’ of therapy, it might be expected that this would
lead to lower clinical effectiveness (see Tarrier and
Wykes
49 for a full discussion of the validity issues in
CBT studies). In the future, trials of CBTp or any psy-
chological treatment need to include some measure of
the ‘‘effective dose’’ of a specific therapy. This is certainly
not the same as measures for medication therapies which
are simple and generally only refer to the number of days
of treatment at a specified level. A sophisticated but
simple-to-apply measure for psychological treatments
needs to include aspects of the therapy process—eg, how
many specific CBTp sessions has the person received.
This might be gleaned from a simple process measure col-
lected by the therapist and later tested for reliability.
Inaddition,wewerenotabletoassessadequatelysome
of the external validation factors, such as treatment gen-
eralization, because most studies recruited patients from
a convenience sample (ie, through referrals from other
agencies) and were relatively small. How participants en-
ter into a trial and the pool from which they were
recruited can greatly affect the ease of treatment and po-
tentially the treatment response. Developments in back-
ground mental health services over time and the
differences between available services between different
locations, such as the United Kingdom and United
States, can also make comparisons difficult. This is
true both between different studies and within a study be-
tween experimental and control groups when both re-
ceive standard care or TAU. The nature of TAU can
be extremely varied. An investigation of this was beyond
the scope of this review and must wait until there are
larger numbers of studies. We hoped to capture some
of the differences by looking at country of origin, but
this is not a very clean variable. Participant willingness
to enter a trial may also be affected by the nature and
accessibility of alternative care from standard services.
These are issues which might be expected to potentially
influence trial results but are rarely considered or
assessed other than in the folklore of the academic
community.
While still supporting the use of CBTp in schizophre-
nia we wish to caution against exaggerated claims of the
magnitude of treatment benefit. Many of the studies in-
volvedinourmeta-analysiswerecarriedoutbyorunder
the supervision of the experts in CBTp. There have been
some studies showing that after specialist training
CBTp can be of value in local service either by training
psychiatrists or nurses in key skills. But in order to op-
timize the treatment effects in local services, it may be
necessary to provide specific training in the clinical
models that are most successful. There is some indica-
tion of a bias toward the use of behavioral features
although the specific successful ingredients of the un-
derlying models have not yet been investigated. How ef-
fective novel treatments are disseminated into the wider
mental health service is a challenge that sometimes
results in unanticipated difficulties.
94 The hope that
CBTp would become widely available through brief
training to less well-qualified and skilled staff is not
borne out by experience. But the cost of CBTp being
delivered by well-trained and experienced psychologists
should not preclude the adoption of CBTp into mental
health services. Even if group treatments were an alter-
native and perhaps cost-effective, these too require ex-
perienced and trained personnel to carry them out. The
fact that organ transplants can only be carried out by
experienced and skilled surgeons is not advanced as
a reason to restrict transplant surgery. In mental health
services,cheapandineffectivealternativesshouldnotbe
a viable option to useful, valued, and effective but more
expensive ones.
Despite the current acceptance of CBTp in treatment
guidance and in some service settings—particularly the
United Kingdom—we still need more information if
we are to provide CBTp effectively and efficiently. The
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assume that, once the therapy has been accepted, it
requires no further investment; so we have set out
some key features of a future CBTp research program.
It should include
  methodologically rigorous efficacy trials of well-
defined treatment programs,
  measures of treatment process which allow an estimate
of the dose of treatment that is more sophisticated than
‘‘number of sessions,’’
  outcome measures that are acceptable not only to the
clinical and academic community but also to the
patients themselves,
  studies of effectiveness with different models, staff
training methods, and background service provision,
  long-term follow-up studies of the durability of treat-
ment effects.
This program will produce a refinement of treatment
that has been tested using rigorous methods and is there-
fore likely to offer the most benefit to people with con-
tinuing positive symptoms of schizophrenia.
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